DEEP TRACK CAPITAL LP
Q4 2025 Form 13-F
GREENWICH, CONNECTICUT
CIK 0001856083
· CRD 312459
· SEC-registered investment adviser
$5.6B Reported Value Total
DEEP TRACK CAPITAL, LP reports 3 total accounts under management (AUM). There are 3 discretionary accounts valued at $5,194,322,737, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
2 funds
· $8.4B gross asset value
Hedge Fund: $8.4B
Source: Form ADV filed 2026-03-31
Reported value
$5.6B
Quarter over quarter
+47.0%
Holdings
53
Top-10 concentration
60.2%
Key People
Form ADV owners & control persons
David Eric Kroin
MANAGING MEMBER
Nir Salman Messafi
CHIEF OPERATING AND FINANCIAL OFFICER / CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q4 2025 13F record
Q4 2025 13F filing summary
| Period of report | December 31, 2025 |
|---|---|
| Filed | February 13, 2026 |
| Form | 13F-HR |
| Reported value | $5.6B |
| Positions | 53 |
| Change in reported value | +56.5% |
| New positions | 15 |
| Exited positions | 18 |
| Position turnover | 46.5% |
| Top-10 concentration | 60.2% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
71 | $6.1B |
|
Q2 2026 13F
Filed Aug 14, 2026
|
66 | $6.9B |
|
Q1 2026 13F
Filed May 15, 2026
|
62 | $6.1B |
|
Q4 2025 13F
Filed Feb 13, 2026
|
53 | $5.6B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
56 | $3.6B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
65 | $3.1B |
|
Q1 2025 13F
Filed May 15, 2025
|
69 | $3.1B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
61 | $2.7B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
69 | $3.2B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
67 | $3.4B |
|
Q1 2024 13F
Filed May 15, 2024
|
65 | $3.5B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
57 | $3.0B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
62 | $2.6B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
53 | $2.2B |
|
Q1 2023 13F
Filed May 15, 2023
|
54 | $2.4B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
57 | $2.4B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
60 | $2.2B |
|
Q2 2022 13F
Filed Aug 12, 2022
|
49 | $1.5B |
|
Q1 2022 13F
Filed May 16, 2022
|
49 | $1.6B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
49 | $1.4B |
Top 20 holdings · Q4 2025
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | XBI P SPDR SERIES TRUST | $1.2B | 21.74% |
| 2 | IMVT IMMUNOVANT INC | $293.0M | 5.22% |
| 3 | GH GUARDANT HEALTH INC | $286.0M | 5.1% |
| 4 | GPCR STRUCTURE THERAPEUTICS INC | $286.0M | 5.1% |
| 5 | TARS TARSUS PHARMACEUTICALS INC | $246.0M | 4.39% |
| 6 | DVAX DYNAVAX TECHNOLOGIES CORP | $241.9M | 4.31% |
| 7 | CYTK CYTOKINETICS INC | $212.0M | 3.78% |
| 8 | AXSM AXSOME THERAPEUTICS INC | $210.0M | 3.74% |
| 9 | APLS APELLIS PHARMACEUTICALS INC | $194.7M | 3.47% |
| 10 | PCVX VAXCYTE INC | $184.6M | 3.29% |
| 11 | MAZE MAZE THERAPEUTICS INC | $175.9M | 3.14% |
| 12 | VERA VERA THERAPEUTICS INC | $142.9M | 2.55% |
| 13 | BMRN BIOMARIN PHARMACEUTICAL INC | $136.7M | 2.44% |
| 14 | IONS IONIS PHARMACEUTICALS INC | $134.5M | 2.4% |
| 15 | NRIX NURIX THERAPEUTICS INC | $133.5M | 2.38% |
| 16 | MBX MBX BIOSCIENCES INC | $102.5M | 1.83% |
| 17 | OCUL OCULAR THERAPEUTIX INC | $98.0M | 1.75% |
| 18 | GRAL GRAIL INC | $87.5M | 1.56% |
| 19 | VRDN VIRIDIAN THERAPEUTICS INC | $78.6M | 1.4% |
| 20 | LBRX LB PHARMACEUTICALS INC | $74.6M | 1.33% |
Values as reported on the Q4 2025 Form 13F. Every position is in the holdings table below.